Clinical utility of EBV DNA testing of blood in immunocompetent and immunocompromised patients: A single-center experience
EBV NAAT testing infrequently influenced clinical management in immunocompetent individuals but had a notable impact in immunocompromised patients, particularly those undergoing posttransplant or malignancy screening. This underscores the need for targeted testing to optimize resource utilization and cost-effectiveness.
Authors
- Camille N. Kotton (ORCID: https://orcid.org/0000-0001-7320-2234)
- Erik H. Klontz (ORCID: https://orcid.org/0000-0002-1923-972X)
- Sarah E. Turbett (ORCID: https://orcid.org/0000-0002-3603-8110)
- Simran Gupta (ORCID: https://orcid.org/0000-0002-2006-1236)
Institutions
- Harvard University (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- American Journal of Clinical Pathology
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1093/ajcp/aqae143
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00